Lung cancer is among the top deadliest and most common cancers in Thailand. Prevention or modifying at-risk behaviors would mitigate this public health crisis just as much as early diagnosis. Tumor markers are released by the body in response to cancer cells or in some cases are released by actual cancer cells. Current biomarkers are being assessed to identify and assess treatment response/therapeutic response and patient’s prognosis, but none has indicated early diagnosis or differentiate lung cancer patients from others with similar symptoms.
Vascular endothelial growth factor (VEGF) is a signal protein produced by cells that stimulates angiogenesis. Due to its predictive values of prognosis in lung cancer patients, researchers take interest in identifying its role in lung cancer prognosis.
The study of VEGF measurement (pic 1) shows remarkable increased level of the markers in the blood of lung cancer patients when compared to that of 1) patients with other lung diseases 2) healthy individuals 3) combination of healthy individuals and individuals suffering from other lung diseases. Picture 1 shows VEGF level in blood/ VEGF concentration in blood/ patients with other lung diseases/ healthy individuals/combined group/patients with lung cancer.
The study will undoubtedly benefit the effort in early diagnosis of lung cancer as well as development of a fast, efficient, low-cost diagnostic process.
Dr. Pritsana Ruangrat and team
Department of Biomedical Sciences, Faculty of Medicine, Prince of Songkla University